Login to Your Account



WASHINGTON ROUNDUP

CRS: Biosimilar competition not likely in the short-term

By Mari Serebrov
Washington Editor

Monday, February 3, 2014
With an eye on enhancing biologic competition, the FTC is diving into some of the issues that will shape the biosimilar market in the U.S. But the Congressional Research Service (CRS) isn’t holding its breath as it waits for the competition to hit.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription